BioMarin Pharmaceutical Raises FY2026 Adj EPS Guidance from $4.85-$5.05 to $4.90-$5.10 vs $3.64 Est; Raises FY2026 Sales Guidance from $3.82
BioMarin Pharmaceutical (NASDAQ: BMRN ) raises FY2026 Adj EPS guidance from $4.85-$5.05 to $4.90-$5.10 vs $3.64 analyst estimate. Raises FY2026 sales outlook from $3.825 billion-$3.925 billion to $3.875 billion-$3.925 billion vs $3.875 billion estimate.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.